NEKTAR THERAPEUTICS 8-K

What Happened

• On April 20, 2026, Nektar Therapeutics (NKTR) filed an 8-K under Item 7.01 (Regulation FD Disclosure) announcing that it had approximately $741.7 million in cash and investments in marketable securities as of April 1, 2026.
• The company stated these figures are estimates based on information available as of the announcement date and are not a comprehensive statement of its operating results or overall financial position.

Key Details

• Reported amount: approximately $741.7 million in cash and marketable securities.
• Snapshot date: as of April 1, 2026.
• Filing date: announcement made and 8-K filed on April 20, 2026 under Item 7.01 (Regulation FD Disclosure).
• Disclosure note: amounts are estimates and not a full statement of operating results or financial position.

Why It Matters

• This disclosure gives investors a current snapshot of Nektar’s liquidity (cash and short-term investments) as of April 1, 2026.
• While not a replacement for full quarterly or annual financial statements, the figure is useful when assessing the company’s cash resources relative to upcoming expenditures, development programs, or other corporate needs.
• Investors should consider this alongside official financial reports (earnings, revenue, expenses) and future filings for a complete view of Nektar’s financial condition.